Genzyme Could Have Other Suitors: Report

Besides France's Sanofi-Aventis, Genzyme's potential suitors might include GlaxoSmithKline and Johnson and Johnson, a report says.
Author:
Publish date:

CAMBRIDGE, Mass. (

TheStreet

) -- Besides France's

Sanofi-Aventis

(SNY) - Get Report

, Genzyme's potential suitors might include

GlaxoSmithKline

(GSK) - Get Report

and

Johnson and Johnson

(JNJ) - Get Report

, a report says.

News of Sanofi's interest in Genzyme

, the U.S. biotechnology company, became public Friday and Britain's GlaxoSmithKline and J&J are seen as the other most logical suitors for Genzyme, bankers and analysts said, according to the

Wall Street Journal

.

Glaxo recently made a very casual approach to Genzyme, telling executives there to keep Glaxo company in mind if Genzyme thought about selling itself, a person familiar with the matter told the

Journal

. But the contact ended there and there hasn't been continuing dialogue after the casual expression of interest, these people said.

Glaxo and and Johnson & Johnson declined to comment for the newspaper.

Genzyme had $4.5 billion in sales last year.

-- Written by Joseph Woelfel in New York.

Get more stock ideas and investing advice on our sister site,

Stockpickr.com.